Overview
- The Federal Trade Commission filed a 123-page lawsuit in federal court in Texas on June 17, 2026, joined by Alaska, Iowa, Nebraska and Texas, alleging WPATH misled parents and clinicians about puberty blockers, cross-sex hormones and surgeries for minors.
- The complaint cites internal WPATH drafting messages that said guidelines should be written to ‘guarantee insurance coverage’ and alleges the group removed age limits and downplayed risks when publishing its 2022 Standards of Care (SOC-8).
- The FTC asks a judge to bar future misleading claims, impose civil penalties and award state-level remedies that could affect how insurers classify and pay for pediatric gender-affirming treatments.
- WPATH denies the charges, says the FTC lacks jurisdiction over its noncommercial guidance, and has already won a temporary court order this year blocking some of the agency’s investigative demands, setting up a likely multi-front legal fight over procedure and free speech.
- Reporting divides along political lines with conservative outlets highlighting alleged patient harms and profit motives while more centrist and liberal outlets warn the move expands the FTC into medical guideline review; the case could also influence parallel probes of other medical societies and alter access to care if insurers or hospitals change coverage.